

(19) **DANMARK**

(10) **DK/EP 2631297 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **C 12 N 15/85 (2006.01)** **C 07 K 14/035 (2006.01)** **C 07 K 14/05 (2006.01)**
C 07 K 19/00 (2006.01) **C 12 N 15/869 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2017-08-07**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2017-04-12**
- (86) Europæisk ansøgning nr.: **12192258.7**
- (86) Europæisk indleveringsdag: **2009-03-09**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-08-28**
- (30) Prioritet: **2008-05-15 US 71760 P**
- (62) Stamansøgningsnr: **09745326.0**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR**
- (73) Patenthaver: **NATIONAL RESEARCH COUNCIL OF CANADA, 1200 Montréal Road, Ottawa, Ontario K1A 0R6, Canada**
- (72) Opfinder: **DUROCHER, Yves, 5335 Place d'Argenteuil, Montreal, Quebec H4J 1M1, Canada**
LOIGNON, Martin, 23 Tarragone, Kirkland, Quebec H9J 1R4, Canada
- (74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Bredgade 30, 1260 København K, Danmark**
- (54) Benævnelse: **FREMGANGSMÅDE, VEKTORER OG MANIPULEREDE CELLELINJER TIL AT FORBEDRE TRANSFEKTION I STOR MÅLESTOK**
- (56) Fremdragne publikationer:
WO-A1-2007/048601
YASUFUMI KANEDA: "Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector.", HUMAN GENE THERAPY, vol. 11, 10 February 2000 (2000-02-10), pages 471-479, XP055072160,
KISHIDA T ET AL: "Application of EBV-based artificial chromosome to genetic engineering of mammalian cells and tissues", MICRO-NANOMECHATRONICS AND HUMAN SCIENCE, 7 November 2005 (2005-11-07), pages 124-129, XP010890408, DOI: 10.1109/MHS.2005.1589976 ISBN: 978-0-7803-9482-7

DESCRIPTION

Cross-reference to Related Applications

[0001] This application claims the benefit of United States Provisional Patent Application USSN 61/071,760 filed May 15, 2008.

Field of the Invention

[0002] The present invention relates to processes, vectors and engineered cell lines for large-scale transfection and protein production.

Background of the Invention

[0003] Large-scale transfection of Chinese Hamster Ovary (CHO) cells with cost-effective reagents for the production of r-proteins suffers from low efficiency and low productivity. In addition, plasmid vectors used in CHO cells are not fully optimized for transient gene expression.

[0004] There are some very efficient and commercially available cationic lipids formulation that can be used to transfect CHO cells in serum-free medium, for example FreestyleMax™ from Invitrogen. However, these cationic lipids are very expensive. Also, to improve productivity, it is becoming current practice to lower the cultivation temperature following transfection to prolong the production phase and to enhance productivity. This temperature shift is not "user friendly" when working at large-scale or when using non-refrigerated culture devices (Wave bioreactors, etc). Also, the exact temperature at which the shifts are done may be critical for getting optimal enhancement (e.g. 29 vs. 30 vs. 31 vs. 32 degrees Celsius).

[0005] International patent publication WO 2007/048601 reports an expression system in CHO cells stably expressing EBNA1 for the production of r-proteins. However, this document specifically admonishes that the cell lines shall not contain a functional copy of the Epstein-Barr virus (EBV) oriP sequence. Further, the full length EBNA1 structural gene encoding a full length EBNA1 protein is transfected into the cell line, and the oriP sequence is never in the same vector as the EBNA1 gene construct.

[0006] International patent publication WO 2002/090533 describes enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells. However, only full length EBNA1 structural genes are used encoding full length EBNA1 proteins and only transient expression of a gene of interest is achieved.

[0007] International patent publication 2006/096989 describes expression vectors for enhanced transient gene expression and mammalian cells expressing them. However, only HEK293 cell lines are exemplified and the expression system used does not contain both the EBNA1 gene construct and the oriP sequence in the same vector. Further, only transient expression of a gene of interest is achieved.

[0008] There is a need in the art for processes, vectors and engineered cell lines for more efficient and productive transfection of cells at a large scale.

Summary of the Invention

[0009] In accordance with a first aspect of the present invention, there is provided an expression system for stable expression of a gene of interest, the expression system comprising: a first vector having an Epstein-Barr virus nuclear antigen-1 (EBNA1) nucleotide sequence encoding a protein that consists of EBNA1c, EBNA1t, or EBNA1s as depicted in Figure 1, a promoter and a polyadenylation signal for the EBNA1 nucleotide sequence and an oriP nucleotide sequence; and, a second vector having a gene of interest, a promoter and a polyadenylation signal for the gene of interest and an oriP nucleotide sequence.

[0010] In accordance with a second aspect of the present invention, there is provided an in vitro method of stably expressing a gene of interest in mammalian cells, the method comprising: transfecting a mammalian cell with an expression system for stable expression of a gene of interest, the expression system comprising: a first vector having an Epstein-Barr virus nuclear antigen-1 (EBNA1) nucleotide sequence encoding a protein that consists of EBNA1c, EBNA1t, or EBNA1s as depicted in Figure 1, a promoter and a polyadenylation signal for the EBNA1 nucleotide sequence and an oriP nucleotide sequence; and, a second vector having a gene of interest, a promoter and a polyadenylation signal for the gene of interest and an oriP nucleotide sequence; and, replicating the cell to provide mammalian cells that stably express the gene of interest.

[0011] Further features of the invention will be described or will become apparent in the course of the following detailed description.

Brief Description of the Drawings

[0012] In order that the invention may be more clearly understood, embodiments thereof will now be described in detail by way of example, with reference to the accompanying drawings, in which:

Fig. 1 depicts schematic diagrams of EBNA1 constructs.

Fig. 2 depicts graphs of SEAP activity in CHO cells co-transfected with pTT vectors encoding

various EBNA1 constructs.

Fig. 3A depicts genetic maps of pTT vectors encoding EBNA1c in *cis* under a strong (EF1 α -HTLV; pTT31) or a weak (RSV; pTT34) promoter.

Fig. 3B depicts a graph of SEAP activity in CHO cells transfected with pTT vectors encoding EBNA1c in *cis* under a weak or strong promoter.

Fig. 4A depicts a Western blot of extracts from CHO cells transfected with a linearized pTT-EBNA1c vector containing a blasticidin resistance cassette.

Fig. 4B depicts a Western blot of aliquots of cultures of the CHO cells of Fig. 4A at various time intervals without selection pressure.

Figs. 5A-C depict Western blots of codon optimized EBNA1 expression in HEK293 and CHO cells.

Fig. 5D depicts a graph of secreted alkaline phosphatase (SEAP) activity in CHO cells co-expressing VP16-EBNA1c fusion protein compared to control cells or cells expression an EBNA1c protein.

Fig. 6 depicts graphs of SEAP activity in HEK293 and CHO cells transfected with pTT plasmids using LPEI or LPEI-Max.

Fig. 7 depicts a graph of SEAP activity in transiently transfected CHO-EBNA1c cells illustrating the transactivating activity of oriP.

Fig. 8 depicts a graph of SEAP activity in transfected CHO-EBNA1c cells illustrating the effect of the CMV5 promoter vs. the Elongation Factor 1 α -HTLV (EF1 α -HTLV) hybrid promoter.

Fig. 9 depicts graphs of SEAP activity illustrating the effect of FGF2 (bFGF) co-expression on transient gene expression in HEK293-EBNA1t and CHO-EBNA1c cells.

Fig. 10 depicts a graph of SEAP expression in CHO-EBNA1c cells illustrating protein kinase B (AKT) potentiation of valproic acid (VPA) enhancement of transient gene expression.

Fig. 11 depicts genetic maps of SEAP-encoding pTT plasmids pTT22 (+oriP) and pTT30 (-oriP) and graphs of SEAP activity in CHO-EBNA1c cells transfected with linearized pTT22 and pTT30 plasmids illustrating the effect of oriP on linearized vectors in CHO-EBNA1c cells.

Fig. 12 depicts a graph of SEAP activity in CHO-EBNA1c cells after integration of linearized pTT22 (+oriP) and pTT30 (-oriP) plasmids in their chromosomes.

Description of Preferred Embodiments

Materials and Methods:

[0013] Cell culture: CHO cells are grown at 37°C in FreestyleCHO medium (Invitrogen) supplemented with 8 mM glutamine in Erlenmeyer flasks shaken at 120 rpm in a humidified atmosphere containing 5% CO₂. Cells are routinely maintained between 0.1x10⁶ and 3.0x10⁶ cells/ml. HEK293-EBNA1 cells (clone 6E) are grown at 37°C in F17 medium (Invitrogen) supplemented with 4 mM glutamine and 0.1% pluronic F68 in Erlenmeyer flasks shaken at 120 rpm in a humidified atmosphere containing 5% CO₂. Cells are routinely maintained between 0.1x10⁶ and 2.0x10⁶ cells/ml.

[0014] Cell transfection: For transfection, CHO or HEK293 cells are grown in maintenance medium until they reach a density of 1.5x10⁶ to 2.0x10⁶ cells/ml and then the transfection mixture is added to the cells. For every ml of HEK293 cells to be transfected, 1 µg of plasmid DNA is mixed with 2 µg of 25 kDa linear polyethylenimine as previously described (Durocher, Perret & Kamen, 2002). For every ml of CHO cells to be transfected, 1 µg of plasmid DNA is mixed with 8 µg of 25 kDa linear polyethylenimine or with 6 µg of 40 kDa linear and deacetylated PEI (PEIMAX™ from Polysciences, Inc, catalog #24765-2).

[0015] Secreted alkaline phosphatase activity determination: SEAP activity is measured as previously described using the colorimetric substrate paranitrophenyl phosphate (Durocher et al. 2000).

Single Vector EBV oriP-EBNA1 Stable Expression System:

[0016] Mammalian cells transfected with an expression system in which a single vector contains an Epstein-Barr virus nuclear antigen-1 (EBNA1) nucleotide sequence encoding a truncated EBNA1 protein, an Epstein-Barr Virus (EBV) oriP nucleotide sequence and a gene of interest unexpectedly provide enhanced stable expression of the gene of interest.

[0017] Truncated EBNA1 proteins include, for example, EBNA1c, EBNA1t and EBNA1s. These truncated forms are shown in Fig. 1. EBNA1t is a 417 amino acid protein having DNA Linking Region 1 (LR1) containing Transcriptional Activation Domain (TAD) and DNA Linking Region 2 (LR2) without the Gly-Ala repeats of the 641 amino acid full length protein. EBNA1c is a 306 amino acid protein in which LR2 is present but LR1 is absent, and EBNA1s is a 337 amino acid protein in which LR1 is present but LR2 is absent. EBNA1 nucleotide sequences encoding EBNA1c are preferred in the vector. The amino acid sequences for the full length EBNA1 protein as well as the truncated forms EBNA1t, EBNA1c and EBNA1s are shown in SEQ ID NO: 1-4, respectively. The corresponding nucleotide sequences of the nucleic acid molecules encoding full length EBNA1 and the truncated forms are shown in SEQ ID NO: 5-8, respectively.

[0018] All or any functional part of the complete nucleotide sequence may be used in the vector. The EBV oriP complete nucleotide sequence (pTT3 vector) is shown in SEQ ID NO: 9, and a functional EBV oriP truncated nucleotide sequence (pTT5 vector) is shown in SEQ ID NO: 10. The oriP sequence comprises the Family of Repeats (FR) component and the dyad symmetry (DS) component. The oriP sequence, particularly the FR component, contributes to increased expression and stability of expression of the integrated truncated EBNA1 gene.

[0019] The gene of interest may be any gene that encodes a protein product of interest. Expression of the gene of interest in the transfected cells permits stable, large-scale production of the protein product for industrial purposes. Some particular genes of interest include, for example, genes that encode monoclonal antibodies, erythropoietins, interferons, vascular endothelial growth factors, stem cell growth factors, growth hormones, insulin-like growth factor binding proteins, etc.

[0020] The single vector also preferably comprises a selection gene to permit selection of the transfected cells for the propagation of stable cell lines. Any suitable selection gene may be used. One example of a class of such genes are genes that confer antibiotic resistance on the cell when the vector is transfected into the cell. Some examples within this class include genes that confer resistance to puromycin, blasticidin, geneticin, zeocin or hygromycin. The blasticidin resistance cassette as found in the pYD7 vector is particularly preferred. After transfection of a cell with the vector, the cell may be permitted to replicate. Clones possessing the expression system may be selected on the basis of the selection gene, for example, by treating the cells with an antibiotic and culturing the cells that survive. In this way, a cell line stably expressing the gene of interest may be created.

[0021] Any or all of the nucleotide sequences and/or genes in the integrated vector may be under the control of a promoter also incorporated in the vector. Generally, each gene has its own promoter. Thus, there is preferably a promoter for the EBNA1, a promoter for the gene of interest and a promoter for the selection gene. Strong or weak promoters may be used. Some promoters include, for example, the cytomegalovirus (CMV) promoter, Elongation Factor 1 alpha-HTLV (EF1 α -HTLV) hybrid promoter, and Rous sarcoma virus (RSV) promoter. Also, any or all genes may have a polyadenylation signal. Alternatively, two genes, separated by an Internal Ribosome Entry Site (IRES), can be expressed by using only one promoter and one polyadenylation signal.

[0022] Genetic maps of two embodiments (pTT31-SSH and pTT34-SSH) of the single vector are shown in Fig. 3A. pTT31-SSH is a 8014 bp vector in which the EBNA1c gene is under the control of a strong promoter (EF1 α -HTLV) and the gene of interest (secreted alkaline phosphatase (SEAP) gene) is under the control of a strong promoter (CMV), pTT34-SSH is a 8040 bp vector in which the EBNA1c gene is under the control of a weaker promoter (RSV) and the gene of interest (secreted alkaline phosphatase (SEAP) gene) is under the control of a strong promoter (CMV).

[0023] Fig. 3B depicts a graph of SEAP activity in CHO cells transfected with pTT vectors

(oriP-containing vectors) encoding EBNA1c in *cis* under a weak (RSV) or strong (EF1 α -HTLV) promoter. Referring to Fig. 3B, CHO cells were transfected with increasing amounts of the SEAP gene-containing plasmids pTT-SSH (with oriP but without EBNA1c), pTT31-SSH (with oriP and with EBNA1c under the control of the strong EF1 α -HTLV promoter) and pTT34-SSH (with oriP and with EBNA1c under the control of the weak RSV promoter). Both EBNA1c-containing pTT vectors (pTT31-SSH and pTT34-SSH) lead to an increase in SEAP activity in CHO cells over the non-EBNA1c-containing vector (pTT-SSH). Use of a strong promoter to control EBNA1 expression optimizes levels of transactivating activity thereby optimizing expression of the gene of interest.

[0024] The single vector EBV oriP-EBNA1 expression system is useful in different types of mammalian cells, for example, Chinese Hamster Ovary (CHO) cells, human embryonic kidney 293 (HEK293) cells, Madin-Darby Canine Kidney (MDCK) cells, Vero cells and PER.C6™ cells, especially CHO cells.

Two Vector EBV oriP-EBNA1 Stable Expression System:

[0025] Mammalian cells transfected with an expression system comprising two separate vectors, a first vector containing an Epstein-Barr virus nuclear antigen-1 (EBNA1) nucleotide sequence encoding a truncated EBNA1 protein and an Epstein-Barr Virus (EBV) oriP nucleotide sequence, and a second vector comprising a gene of interest and an Epstein-Barr Virus (EBV) oriP nucleotide sequence unexpectedly provide enhanced stable expression of the gene of interest. The use of oriP in both vectors contributes to stability of expression and increased expression of the gene of interest. To facilitate production of stable cell lines that stably express the gene of interest, both vectors contain selection genes. Selection genes are described above. For example, a stable CHO cell clone expressing EBNA1c driven from an integrated oriP vector containing a blasticidin resistance cassette (pYD7) stably expressed the gene of interest for over 6 months in the absence of selection.

[0026] Stable mammalian cell lines can be produced either by simultaneously transfecting a cell with both vectors and then propagating the cell, or by transfecting a cell with one of the vectors (either the EBNA1-containing or the gene of interest-containing vector) to produce a stable clone and then transfecting a stable clone cell with the other of the vectors to produce a stable clone stably expressing the gene of interest.

[0027] Truncated EBNA1 proteins and corresponding genes, as well as the oriP and genes of interest are described above. As described previously, genes may be under the control of promoters. The two vector EBV oriP-EBNA1 stable expression system is also useful in different types of mammalian cells, for example, Chinese Hamster Ovary (CHO) cells, human embryonic kidney 293 (HEK293) cells, Madin-Darby Canine Kidney (MDCK) cells and PER.C6™ cells, especially CHO cells.

[0028] Referring to Figs. 11 and 12, Chinese Hamster Ovary (CHO) cells stably expressing

EBNA1c were produced by transfecting CHO cells with an EBNA1c oriP-containing plasmid (pYD7 vector) using generally known methods with a linear 25 kDa polyethylenimine (PEI), and stable clones were propagated. One CHO-EBNA1c clone (clone 3E7) so produced was transfected with secreted alkaline phosphatase (SEAP)-encoding and linearized pTT22 (+oriP) or pTT30 (-oriP) vectors. The pTT22 and pTT30 vectors both contain a puromycin resistance cassette. The pTT22 vector contains oriP (i.e. the DS and FR elements are present) while the pTT30 vector does not contain oriP (i.e. the DS and FR elements are removed). CHO-EBNA1c cells transfected with the pTT22 and pTT30 vectors were transferred in 96-well plates at a density of 100 cells/well. Puromycin was added 24 hours post-transfection and selection was maintained for two weeks.

[0029] Referring to Fig. 11, after selection, SEAP activity (mOD/min at 410 nm) was measured in the supernatant at day 14 post-transfection. The results clearly demonstrate the transactivating action of EBNA1c on linearized oriP-bearing expression plasmids integrated in CHO cells. Linearization of the vector abolishes the replication potential of the oriP-EBNA1c system thus eliminating the possibility that the increased SEAP expression is due to plasmid replication. The average SEAP activity for the 96 wells are 46.5 and 5.8 mOD/min for oriP-containing and non-oriP-containing SEAP-encoding vectors, respectively.

[0030] Referring to Fig. 12, after selection, the best positive clones (7 clones for pTT22-oriP vector and 6 clones for pTT30-non-oriP vector) were amplified and maintained in 6-well plates with or without puromycin. Twenty days later, clones were seeded in a 6-well plate at 0.25 million cells per ml and SEAP activity (OD/min at 410 nm) was measured 5 days later. Also shown in Fig. 12 is the SEAP activity found in the non-cloned ("pools" or "bulk") transfected cells maintained in the presence of puromycin for 34 days. SEAP activity in the oriP bulk is 10 times higher than in the non-oriP bulk. These results clearly demonstrate the transactivating action of EBNA1c on integrated oriP-bearing expression plasmids in CHO cells. For clones 4B10 and 4F4, the increased SEAP activity in the presence of puromycin suggests that these two clones are non-clonal and probably contaminated by a cellular population expressing lower levels of SEAP, SEAP activity is expressed as increase in absorbance unit at 410 nm per min (OD/min).

[0031] Thus, the presence of oriP in the integrated expression plasmid confers higher expression levels of the gene of interest in EBNA1-expressing mammalian cells, particularly CHO cells, vs. non-oriP-containing plasmids.

Two Vector Transient Expression System in CHO Cells:

[0032] Chinese Hamster Ovary (CHO) cells transfected with an expression system comprising two separate vectors, a first vector containing an Epstein-Barr virus nuclear antigen-1 (EBNA1) nucleotide sequence encoding a truncated EBNA1 protein and an Epstein-Barr Virus (EBV) oriP nucleotide sequence, and a second vector comprising a gene of interest and an Epstein-Barr Virus (EBV) oriP nucleotide sequence also unexpectedly provide enhanced transient

expression of the gene of interest in the CHO cells.

[0033] CHO cell lines can be produced either by simultaneously transfecting a cell with both vectors and then propagating the cell, or by transfecting a cell with one of the vectors (either the EBNA1-containing or the gene of interest-containing vector) to produce a clone and then transfecting a clone cell with the other of the vectors to produce a clone transiently expressing the gene of interest. Truncated EBNA1 proteins and corresponding genes, as well as the oriP and genes of interest are described above. As described previously, genes may be under the control of promoters.

[0034] Fig. 2 illustrates transient expression of secreted alkaline phosphatase (SEAP) in CHO cells co-transfected with one vector containing oriP plus the SEAP gene and another vector containing oriP plus truncated EBNA1 constructs (EBNA1t, EBNA1c and EBNA1s). In Fig. 2, CHO cells were co-transfected with 50% of pTT-EBNA1 constructs or 50% salmon testis DNA (stDNA) and (45% pTT-SEAP + 5% pTT-GFP) plasmids. SEAP activity was compared to activity in CHO cells transfected with 95% pTT-SEAP + 5% pTT-GFP. SEAP activity (OD/min at 410 nm) was measured 5 days post-transfection. Transfection was accomplished using generally known methods with a linear 25 kDa polyethylenimine (PEI).

[0035] The results in Fig. 2 show an increase in transient SEAP activity of 2-fold or higher in CHO cells co-transfected with oriP/EBNA1 and oriP/SEAP plasmids over CHO cells that are not co-transfected with oriP/EBNA1 plasmids. Further, while it has been previously shown that the "Transcriptional Activation Domain" (aa 65-89) in the LR1 domain of EBNA1 is essential for transcriptional activation of integrated oriP vectors, Fig. 2 surprisingly shows that the truncated EBNA1c construct lacking the LR1 domain but containing the LR2 domain is capable of increasing gene expression from non-integrated criP plasmids to the same level as EBNA1t (that contains both the LR1 and LR2 domains) or EBNA1s (that contains only the LR1 domain).

[0036] In Fig. 4. CHO cells were transfected with a linearized pTT-EBNA1c vector containing a blasticidin resistance cassette (pYD7 vector). Linearization of the vector was achieved following restriction enzyme digestion using PvuI enzyme. Following transfection, cells having stably integrated the pYD7 vector were selected by adding blasticidin to the culture medium. After a few days of blasticidin selection, blasticidin-resistant cells were seeded in 96-well plates without blasticidin selection. Emerging clones were tested for EBNA1c expression. An EBNA1c-positive clone, 3E7 (Fig. 4A), was then selected for further testing. A master cell bank (MCB) and Working cell bank (WCB) were made at this point. The CHO-EBNA1c (clone 3E7) cells were cultured for over 130 days in the absence of blasticidin selection. At various culture time points, an aliquot of the cells were taken for EBNA1c expression analysis by Western blot using an anti-EBNA1 antibody. Fig. 4B shows that the clone 3E7 is very stable over 130 days in culture without blasticidin selection pressure.

[0037] In Fig. 7, CHO cells containing integrated EBNA1-expressing plasmids were produced by transfecting CHO cells with a pTT-EBNA1c vector, and the clone propagated (clone 3E7). Resulting CHO-EBNA1c clone was transfected with SEAP-encoding pTT plasmids with

complete oriP (pTT-SMH), with DS-deleted oriP (pTTi-SMH), with FR-deleted oriP (pTTj-SMH) or with oriP-deleted (pTTI-SMH) pTT vectors. SEAP activity (OD/min at 410 nm) was measured in the supernatant at 5 days post-transfection. Transfections were accomplished using generally known methods with a linear 25 kDa polyethylenimine (PEI).

[0038] The results in Fig. 7 illustrate that increased expression in transiently transfected CHO-EBNA1 cells is due to the transactivating activity of the oriP family of repeats (FR) element, and not to plasmid replication. Removal of the dyad symmetry (DS) element (EBNA1-dependent origin of replication) from the oriP does not inhibit expression while removing the FR element (responsible for EBNA1-dependent transcriptional activation) strongly reduces expression. The results also show that the DS element has a slight inhibitory effect on gene expression.

[0039] Fig. 8 compares the effect of the cytomegalovirus (CMV5) promoter and elongation factor 1 alpha-HTLV (EF1- α HTLV) promoter on transgene expression in CHO-EBNA1c cells (clone 3E7). CHO-EBNA1c-3E7 cells were transfected with increasing amount SEAP-encoding oriP-containing (pTT) plasmids containing either the CMV5 or EF1- α HTLV promoter to control the SEAP gene (the overall content of DNA was kept constant by compensating with non-coding stDNA). SEAP activity (OD/min at 410 nm) was measured in the supernatant at day 6 post-transfection. The results clearly demonstrate that the CMV5 promoter is at least 5 times more potent than the EF1- α HTLV promoter at low plasmid doses (e.g. 5%). Further, CMV5-based plasmid needs 2-4 times less coding plasmid DNA for maximum expression.

Codon-optimized EBNA1 Constructs:

[0040] Codon-optimization of Epstein-Barr virus nuclear antigen-1 (EBNA1) nucleotide sequence strongly enhances expression of EBNA1 in mammalian cells, especially Chinese Hamster Ovary (CHO) and human embryonic kidney (HEK) cells. A codon-optimized EBNA1 cDNA instead of non-codon-optimized EBNA1 cDNA may be used in any of the aspects of the present invention. Full length or truncated EBNA1 cDNA may be codon-optimized. Advantageously, such codon-optimized EBNA1 nucleotide sequences permit the use of weaker promoters to express EBNA1, thereby reducing the likelihood of promoter competition between two strong promoters in a single expression system. Codon-optimized EBNA1c nucleotide sequence (EBNA1c-CO, SEQ ID NO: 13) codes for a 308 amino acid protein (SEQ ID NO: 11). Codon-optimized EBNA1s nucleotide sequence (EBNA1s-CO, SEQ ID NO: 14) codes for a 337 amino acid protein (SEQ ID NO: 12).

[0041] Referring to Fig. 5, EBNA1 constructs (EBNA1c and EBNA1s) were codon-optimized (human codon usage - CO), pTT vectors containing EBNA1c, EBNA1s or their codon-optimized versions (EBNA1c-CO (SEQ ID NO: 13) and EBNA1s-CO (SEQ ID NO: 14)), and empty pTT vector (CTRL) were transfected in separate HEK293 cells or CHO cells by generally known methods with a linear 25 kDa polyethylenimine (PEI). Three days post-transfection, cells were lysed and cell extracts analyzed by Western blot using an anti-EBNA1 antibody. Fig. 5A is a Western blot for cell extracts from HEK293 cells and Fig. 5B is a Western blot for cell extracts

from CHO cells. In both cell lines it is evident that codon optimization enhances transient expression of EBNA1 in the cells when compared to the control (CTRL) and the cells transfected with non-codon-optimized EBNA1.

[0042] For Fig. 5C, HEK293 cells were transfected with increasing amounts (1.25%, 5% and 20%) of pTT vectors containing EBNA1c, EBNA1c-CO, EBNA1s or EBNA1s-CO. Again it is evident from the Western blots in Fig. 5C that codon optimization enhances transient expression of EBNA1 in cells when compared to cells transfected with non-codon-optimized EBNA1.

[0043] For Fig. 5D, CHO cells were co-transfected with pTT-SEAP (50%) plus 5% pTT-GFP vectors (Control) with or without 10% of pTT-EBNA1c, pTT-EBNA1cCO or pTT-VP16/EBNA1cCO (EBNA1cCO fused at its N-terminus to VP16 - see below). Non-coding DNA (stDNA) was used as stuffer DNA to complete the amounts of DNA to 100%. SEAP activity measured 5 days later. This clearly demonstrates that, by improving its expression, codon optimization of EBNA1c provides an increased transactivating activity. A VP16-EBNA1cCO chimera also further increases transient gene expression in CHO cells compared to EBNA1c and EBNA1cCO (see below).

EBNA1c-VP16 Fusion Protein:

[0044] A fusion protein comprising a truncated Epstein-Barr virus nuclear antigen-1c (EBNA1c) protein and a herpes simplex virus protein VP16 provides significantly enhanced transactivating activity in mammalian cells, particularly Chinese Hamster Ovary (CHO) cells and human embryonic kidney (HEK) cells.

[0045] A fusion protein is constructed by fusing VP16 to the N-terminus of codon-optimized EBNA1c. The VP16 cDNA encoding for the following protein sequence was used: APPTDVSLGDELHLDGEDVAMAHADALDDFDLDMLGDGDSPPGPGFTPHDSAPY GALDMADFEFEQMFTDALGIDEYGG (SEQ ID NO: 15). The VP16 cDNA sequence was cloned in-frame to the 5' region of codon-optimized EBNA1c using generally known methods.

[0046] The VP16-EBNA1cCO fusion protein in a pTT plasmid (10%) was co-transfected in CHO cells with pTT-SEAP plasmid (50%) and pTT-GFP plasmid (5%) with a linear 40 kDa deacetylated polyethylenimine (see below). The CHO cells were transfected with 10% pTT/VP16-EBNA1cCO, 50% SEAP, 35% stDNA and 5% GFP. Non-coding DNA (stDNA) was used as stuffer DNA to complete the amounts of DNA to 100%. Five days post-transfection, SEAP activity (OD/min) was measured and compared to activities in cells transfected with stuffer DNA in place of pTT/EBNA1 vectors (CTRL), or a pTT/EBNA1c vector or a pTT/EBNA1cCO vector in place of pTT/VP16-EBNA1c (Fig. 5D). The results in Fig. 5D clearly demonstrate that a VP16-EBNA1cCO chimera further increases transient gene expression in CHO cells compared to EBNA1c or EBNA1cCO.

Transfection with Fully Deacylated PEI:

[0047] Use of a 40 kDa fully deacetylated poly(ethylenimine) (LPEI-MAX) as a transfection reagent unexpectedly improves transfection efficiency and/or productivity in Chinese Hamster Ovary (CHO) cells in comparison to the use of the usual linear 25 kDa poly(ethylenimine) (LPEI). Such an improvement is not realized in human embryonic kidney (HEK) cells.

[0048] Referring to Fig. 6, HEK293-EBNA1t (clone 6E) and CHO-EBNA1c (clone 3E7) cells were used. For the upper panel of Fig. 6, HEK293-EBNA1t cells were transfected with pTT-SEAP plasmids using LPEI-MAX at various DNA:PEI ratios (R) and polyplexes amounts (%). SEAP activity (OD/min at 410 nm) was measured in the supernatant 6 days post transfection and compared to the best condition found for LPEI (75% polyplexes; R=1:2). The results in the upper panel show that LPEI-Max is not better than LPEI in HEK293 cells. For the lower panel, CHO-EBNA1 cells were transfected with pTT-SEAP plasmids using LPEI-MAX at various DNA:PEI ratios. SEAP activity (OD/min at 410 nm) was measured in the supernatant 6 days post transfection and compared to the best condition found for LPEI (1:8). The results in the lower panel clearly demonstrate that LPEI-MAX is significantly more potent than LPEI in CHO cells for transient gene expression.

Co-expression of FGF:

[0049] Co-expression of a fibroblast growth factor (FGF) increases heterologous gene expression in Chinese Hamster Ovary (CHO) cells.

[0050] Referring to Fig. 9, graphs are shown illustrating the effect of FGF2 (bFGF) co-expression on transient gene expression in HEK293-EBNA1t (clone 6E) cells (upper panel) and CHO-EBNA1c (clone 3E7) cells (lower panel). The HEK293-EBNA1t and CHO-EBNA1c cells were transfected with 25% pTT-SEAP vector and increasing amounts (0%, 15%, 30%, 45%, 60% and 70%) of FGF2-encoding pTT plasmid (the overall content of DNA was kept constant with non-coding stDNA). SEAP activity (OD/min at 410 nm) was measured in the supernatant 7 days post-transfection. From the upper panel it is evident that SEAP activity in HEK293-EBNA1t cells is decreased by co-expression of FGF2. From the lower panel it is evident that SEAP activity in CHO-EBNA1c cells is increased by co-expression of FGF2. This clearly demonstrates that the co-expression of FGF2 enhances transgene expression in CHO cells but not in HEK293 cells. Increased productivity in CHO cells may be due to a FGF-induced rRNA synthesis.

PKB Potentiation of VPA:

[0051] Use of protein kinase B (PKB) to potentiate valproic acid (VPA) increases heterologous

gene expression in mammalian cells, especially Chinese Hamster Ovary (CHO) cells.

[0052] Valproic acid (VPA), a histone deacetylase inhibitor, enhances transient gene expression in cells. However, VPA also induces apoptosis thereby killing cells and reducing overall gains in productivity. It has now been found that co-expressing PKB (also known as AKT) or a constitutively active PKB mutant in the cells potentiates the action of valproic acid in gene expression by inhibiting apoptosis.

[0053] Referring to Fig. 10. the effect of PKB (AKT) and valproic acid (VPA) on transient gene expression in CHO-EBNA1c (clone 3E7) cells is illustrated. The CHO-EBNA1c cells were transfected with a mixture of SEAP-encoding oriP plasmids (pTT-SEAP) and stuffer DNA or pTT-AKTdd vector (AKTdd is a dominant-positive mutant of AKT). In some cases, 0.25 mM VPA was added 24 hours post-transfection. SEAP activity ($\Delta A_{410}/\text{min}$) was measured at days 5 to 8 post-transfection. Fig. 10 clearly demonstrates that valproic acid increases transient gene expression in CHO cells and that transient co-expression of AKTdd greatly potentiates this effect.

References:

[0054]

Mizuguchi H, Hosono T, Hayakawa T. Long-term replication of Epstein-Barr virus-derived episomal vectors in the rodent cells. *FEBS Lett* 2000 Apr 28;472(2-3):173-8.

Durocher, Y, Perret, S, Thibaudeau, E, Gaumond, MH, Kamen, A, Stocco, R, Abramovitz, M. A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. *Analytical Biochemistry* 2000 Sep 10, 284 (2):316-26.

Boussif O, Zanta MA, Behr JP. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. *Gene Ther* 1996 Dec;3(12):1074-80.

Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klivanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. *Proc Natl Acad Sci U S A* 2005 Apr 19;102(16):5679-84.

Kang MS, Hung SC, Kieff E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. *Proc Natl Acad Sci U S A* 2001 Dec 18;98(26):15233-8.

Sears J, Kolman J, Wahl GM, Aiyar A. Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1. *J Virol* 2003 Nov;77(21):11767-80.

Kennedy G, Sugden B. EBNA1, a bifunctional transcriptional activator. *Mol Cell Biol* 2003

Oct;23(19):6901-8.

Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J Biol Chem* 2001 Sep 28;276(39):36734-41.

Chen J, Ghazawi FM, Bakkar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. *Mol Cancer* 2006;5:71.

Sheng Z, Liang Y, Lin CY, Comai L, Chirico WJ. Direct regulation of rRNA transcription by fibroblast growth factor 2. *Mol Cell Biol* 2005 Nov;25(21):9419-26.

Kishida T, Asada H, Kubo K, Sato YT, Shin-Ya M, Imanishi J, Yoshikawa K, Mazda O. Pleiotrophic functions of Epstein-Barr virus nuclear antigen-1 (EBNA1) and oriP differentially contribute to the efficacy of transfection/expression of exogenous gene in mammalian cells. *Journal of Biotechnology* 2007.

Ettehadieh E, Wong-Madden S, Aldrich T, Lane K, Morris AE. Over-expression of protein kinase B α enhances recombinant protein expression in transient systems. *Cytotechnology* 2002; 38:11-14.

Krysan PJ, Calos MP. Epstein-Barr virus-based vectors that replicate in rodent cells. *Gene* 1993; 137-143.

Tomiyasu K, Satoh E, Oda Y, Nishizaki K, Kondo M, Imanishi J, Mazda O. Gene transfer in vivo and in vitro with hEpstein-Barr virus-based episomal vector results in markedly high transient expression in rodent cells. *Biochem Biophys Res Comm* 1998; 253: 733-738.

Goepfert U, Kopetzki E. Protein expression in rodent cells. International Patent Publication WO 2007/048601 published 3 May 2007.

Sunstrom NA, Kunaparaju R. Rodent expression system utilising polyoma virus and Epstein-Barr virus sequences. International Patent Publication WO 2005/024030 published 17 March 2005.

Durocher Y, Perret S, Pham PL, St-Laurent G, Kamen A. Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells. International Patent Publication WO 2002/090533 published 14 November 2002.

Durocher Y. Expression vectors for enhanced transient gene expression and mammalian cells expressing them. International Patent Publication WO 2006/096989 published 21 September 2006.

SEQUENCE LISTING

[0055]

<110> National Research Council of Canada

Durocher, Yves

Loignon, Martin

<120> PROCESS, VECTORS AND ENGINEERED CELL LINES FOR ENHANCED LARGE-SCALE TRANSFECTION

<130> 11992-98

<150> US 61/071,760

<151> 2008-05-15

<160> 15

<170> PatentIn version 3.5

<210> 1

<211> 641

<212> PRT

<213> Epstein Barr Virus

<220>

<221> MISC_FEATURE

<223> EBNA1 Full Length Protein

<400> 1

```

Met Ser Asp Glu Gly Pro Gly Thr Gly Pro Gly Asn Gly Leu Gly Glu
 1           5           10           15

Lys Gly Asp Thr Ser Gly Pro Glu Gly Ser Gly Gly Ser Gly Pro Gln
 20           25           30

Arg Arg Gly Gly Asp Asn His Gly Arg Gly Arg Gly Arg Gly Arg Gly
 35           40           45

Arg Gly Gly Gly Arg Pro Gly Ala Pro Gly Gly Ser Gly Ser Gly Pro
 50           55           60

Arg His Arg Asp Gly Val Arg Arg Pro Gln Lys Arg Pro Ser Cys Ile
 65           70           75           80

Gly Cys Lys Gly Thr His Gly Gly Thr Gly Ala Gly Ala Gly Ala Gly
 85           90           95

Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Ala Gly
100           105           110

Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly
115           120           125

```

Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala
 130 135 140

Gly Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly Ala Gly
 145 150 155 160

Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly
 165 170 175

Ala Gly Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly
 180 185 190

Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Ala Gly Gly Ala Gly
 195 200 205

Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala
 210 215 220

Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala
 225 230 235 240

Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly
 245 250 255

Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly
 260 265 270

Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly
 275 280 285

Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly
 290 295 300

Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Ala Gly
 305 310 315 320

Gly Ala Gly Ala Gly Gly Gly Gly Gly Arg Gly Arg Gly Gly Ser Gly Gly
 325 330 335

Arg Gly Arg Gly Gly Ser Gly Gly Arg Gly Arg Gly Gly Ser Gly Gly
 340 345 350

Arg Arg Gly Arg Gly Arg Glu Arg Ala Arg Gly Gly Ser Arg Glu Arg
 355 360 365

Ala Arg Gly Arg Gly Arg Gly Arg Gly Glu Lys Arg Pro Arg Ser Pro
 370 375 380

Ser Ser Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg Pro Pro Pro
 385 390 395 400

Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp Tyr Phe Glu
 405 410 415

Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val Pro Pro Gly
 420 425 430

Ala Ile Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu Gly Pro Ser Thr
435 440 445

Gly Pro Arg Gly Gln Gly Asp Gly Gly Arg Arg Lys Lys Gly Gly Trp
450 455 460

Phe Gly Lys His Arg Gly Gln Gly Gly Ser Asn Pro Lys Phe Glu Asn
465 470 475 480

Ile Ala Glu Gly Leu Arg Ala Leu Leu Ala Arg Ser His Val Glu Arg
485 490 495

Thr Thr Asp Glu Gly Thr Trp Val Ala Gly Val Phe Val Tyr Gly Gly
500 505 510

Ser Lys Thr Ser Leu Tyr Asn Leu Arg Arg Gly Thr Ala Leu Ala Ile
515 520 525

Pro Gln Cys Arg Leu Thr Pro Leu Ser Arg Leu Pro Phe Gly Met Ala
530 535 540

Pro Gly Pro Gly Pro Gln Pro Gly Pro Leu Arg Glu Ser Ile Val Cys
545 550 555 560

Tyr Phe Met Val Phe Leu Gln Thr His Ile Phe Ala Glu Val Leu Lys
565 570 575

Asp Ala Ile Lys Asp Leu Val Met Thr Lys Pro Ala Pro Thr Cys Asn
580 585 590

Ile Arg Val Thr Val Cys Ser Phe Asp Asp Gly Val Asp Leu Pro Pro
595 600 605

Trp Phe Pro Pro Met Val Glu Gly Ala Ala Ala Glu Gly Asp Asp Gly
610 615 620

Asp Asp Gly Asp Glu Gly Gly Asp Gly Asp Glu Gly Glu Glu Gly Gln
625 630 635 640

Glu

<210> 2

<211> 417

<212> PRT

<213> Epstein Barr Virus

<220>

<221> MISC_FEATURE

<223> EBNA1t Truncated Protein

<400> 2

Met Ser Asp Glu Gly Pro Gly Thr Gly Pro Gly Asn Gly Leu Gly Glu
1 5 10 15

Lys Gly Asp Thr Ser Gly Pro Glu Gly Ser Gly Gly Ser Gly Pro Gln
 20 25 30
 Arg Arg Gly Gly Asp Asn His Gly Arg Gly Arg Gly Arg Gly Arg Gly
 35 40 45
 Arg Gly Gly Gly Arg Pro Gly Ala Pro Gly Gly Ser Gly Ser Gly Pro
 50 55 60
 Arg His Arg Asp Gly Val Arg Arg Pro Gln Lys Arg Pro Ser Cys Ile
 65 70 75 80
 Gly Cys Lys Gly Thr His Gly Gly Thr Gly Ala Gly Ala Gly Ala Gly
 85 90 95
 Gly Ala Gly Ala Gly Gly Gly Gly Arg Gly Arg Gly Gly Ser Gly Gly
 100 105 110
 Arg Gly Arg Gly Gly Ser Gly Gly Arg Gly Arg Gly Gly Ser Gly Gly
 115 120 125
 Arg Arg Gly Arg Gly Arg Glu Arg Ala Arg Gly Gly Ser Arg Glu Arg
 130 135 140
 Ala Arg Gly Arg Gly Arg Gly Arg Gly Glu Lys Arg Pro Arg Ser Pro
 145 150 155 160
 Ser Ser Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg Pro Pro Pro
 165 170 175
 Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp Tyr Phe Glu
 180 185 190
 Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val Pro Pro Gly
 195 200 205
 Ala Ile Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu Gly Pro Ser Thr
 210 215 220
 Gly Pro Arg Gly Gln Gly Asp Gly Gly Arg Arg Lys Lys Gly Gly Trp
 225 230 235 240
 Phe Gly Lys His Arg Gly Gln Gly Gly Ser Asn Pro Lys Phe Glu Asn
 245 250 255
 Ile Ala Glu Gly Leu Arg Ala Leu Leu Ala Arg Ser His Val Glu Arg
 260 265 270
 Thr Thr Asp Glu Gly Thr Trp Val Ala Gly Val Phe Val Tyr Gly Gly
 275 280 285
 Ser Lys Thr Ser Leu Tyr Asn Leu Arg Arg Gly Thr Ala Leu Ala Ile
 290 295 300
 Pro Gln Cys Arg Leu Thr Pro Leu Ser Arg Leu Pro Phe Gly Met Ala
 305 310 315 320

Pro Gly Pro Gly Pro Gln Pro Gly Pro Leu Arg Glu Ser Ile Val Cys
 325 330 335

Tyr Phe Met Val Phe Leu Gln Thr His Ile Phe Ala Glu Val Leu Lys
 340 345 350

Asp Ala Ile Lys Asp Leu Val Met Thr Lys Pro Ala Pro Thr Cys Asn
 355 360 365

Ile Arg Val Thr Val Cys Ser Phe Asp Asp Gly Val Asp Leu Pro Pro
 370 375 380

Trp Phe Pro Pro Met Val Glu Gly Ala Ala Ala Glu Gly Asp Asp Gly
 385 390 395 400

Asp Asp Gly Asp Glu Gly Gly Asp Gly Asp Glu Gly Glu Glu Gly Gln
 405 410 415

Glu

<210> 3

<211> 306

<212> PRT

<213> Epstein Barr Virus

<220>

<221> MISC_FEATURE

<223> EBNA1c Truncated Protein

<400> 3

Met Arg Gly Arg Gly Gly Ser Gly Gly Arg Gly Arg Gly Gly Ser Gly
 1 5 10 15

Gly Arg Arg Gly Arg Gly Arg Glu Arg Ala Arg Gly Gly Ser Arg Glu
 20 25 30

Arg Ala Arg Gly Arg Gly Arg Gly Arg Gly Glu Lys Arg Pro Arg Ser
 35 40 45

Pro Ser Ser Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg Pro Pro
 50 55 60

Pro Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp Tyr Phe
 65 70 75 80

Glu Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val Pro Pro
 85 90 95

Gly Ala Ile Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu Gly Pro Ser
 100 105 110

Thr Gly Pro Arg Gly Gln Gly Asp Gly Gly Arg Arg Lys Lys Gly Gly
 115 120 125

Trp Phe Gly Lys His Arg Gly Gln Gly Gly Ser Asn Pro Lys Phe Glu
130 135 140

Asn Ile Ala Glu Gly Leu Arg Ala Leu Leu Ala Arg Ser His Val Glu
145 150 155 160

Arg Thr Thr Asp Glu Gly Thr Trp Val Ala Gly Val Phe Val Tyr Gly
165 170 175

Gly Ser Lys Thr Ser Leu Tyr Asn Leu Arg Arg Gly Thr Ala Leu Ala
180 185 190

Ile Pro Gln Cys Arg Leu Thr Pro Leu Ser Arg Leu Pro Phe Gly Met
195 200 205

Ala Pro Gly Pro Gly Pro Gln Pro Gly Pro Leu Arg Glu Ser Ile Val
210 215 220

Cys Tyr Phe Met Val Phe Leu Gln Thr His Ile Phe Ala Glu Val Leu
225 230 235 240

Lys Asp Ala Ile Lys Asp Leu Val Met Thr Lys Pro Ala Pro Thr Cys
245 250 255

Asn Ile Arg Val Thr Val Cys Ser Phe Asp Asp Gly Val Asp Leu Pro
260 265 270

Pro Trp Phe Pro Pro Met Val Glu Gly Ala Ala Ala Glu Gly Asp Asp
275 280 285

Gly Asp Asp Gly Asp Glu Gly Gly Asp Gly Asp Glu Gly Glu Glu Gly
290 295 300

Gln Glu
305

<210> 4

<211> 337

<212> PRT

<213> Epstein Barr Virus

<220>

<221> MISC_FEATURE

<223> EBNA1s Truncated Protein

<400> 4

Met Arg Arg Gly Gly Asp Asn His Gly Arg Gly Arg Gly Arg Gly Arg
1 5 10 15

Gly Arg Gly Gly Gly Arg Pro Gly Ala Pro Gly Gly Ser Gly Ser Gly
20 25 30

Pro Arg His Arg Asp Gly Val Arg Arg Pro Gln Lys Arg Pro Ser Cys
35 40 45

Ile Gly Cys Lys Gly Thr His Gly Gly Thr Gly Ala Gly Ala Gly Ala
 50 55 60

Gly Gly Ala Gly Ala Gly Gly Gly Gly Glu Lys Arg Pro Arg Ser Pro
 65 70 75 80

Ser Ser Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg Pro Pro Pro
 85 90 95

Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp Tyr Phe Glu
 100 105 110

Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val Pro Pro Gly
 115 120 125

Ala Ile Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu Gly Pro Ser Thr
 130 135 140

Gly Pro Arg Gly Gln Gly Asp Gly Gly Arg Arg Lys Lys Gly Gly Trp
 145 150 155 160

Phe Gly Lys His Arg Gly Gln Gly Gly Ser Asn Pro Lys Phe Glu Asn
 165 170 175

Ile Ala Glu Gly Leu Arg Ala Leu Leu Ala Arg Ser His Val Glu Arg
 180 185 190

Thr Thr Asp Glu Gly Thr Trp Val Ala Gly Val Phe Val Tyr Gly Gly
 195 200 205

Ser Lys Thr Ser Leu Tyr Asn Leu Arg Arg Gly Thr Ala Leu Ala Ile
 210 215 220

Pro Gln Cys Arg Leu Thr Pro Leu Ser Arg Leu Pro Phe Gly Met Ala
 225 230 235 240

Pro Gly Pro Gly Pro Gln Pro Gly Pro Leu Arg Glu Ser Ile Val Cys
 245 250 255

Tyr Phe Met Val Phe Leu Gln Thr His Ile Phe Ala Glu Val Leu Lys
 260 265 270

Asp Ala Ile Lys Asp Leu Val Met Thr Lys Pro Ala Pro Thr Cys Asn
 275 280 285

Ile Arg Val Thr Val Cys Ser Phe Asp Asp Gly Val Asp Leu Pro Pro
 290 295 300

Trp Phe Pro Pro Met Val Glu Gly Ala Ala Ala Glu Gly Asp Asp Gly
 305 310 315 320

Asp Asp Gly Asp Glu Gly Gly Asp Gly Asp Glu Gly Glu Glu Gly Gln
 325 330 335

Glu

<210> 5

<211> 1926

<212> DNA

<213> Epstein Barr Virus

<220>

<221> misc_feature

<223> EBNA1 Full Length cDNA

<400> 5

atgtctgacg aggggccagg tacaggacct ggaaatggcc taggagagaa gggagacaca	60
tctggaccag aaggctccgg cggcagtgga cctcaaagaa gaggggggtga taaccatgga	120
cgaggacggg gaagaggacg aggacgagga ggcggaagac caggagcccc gggcggctca	180
ggatcagggc caagacatag agatggtgtc cggagacccc aaaaacgtcc aagttgcatt	240
ggctgc aaaag ggaacacag tggaacagga gcaggagcag gaggcgggagg ggcaggagca	300
ggagggggcag gaggcaggagg aggggcagga gcaggagagg gggcaggagg ggcaggaggg	360
gcaggagggg caggagcagg aggaggggca ggagcaggag gaggggcagg aggggcagga	420
ggggcaggag caggagaggagg ggcaggagca ggaggagggg caggaggggc aggagcagga	480
ggagggggcag gaggggcagg aggggcagga gcaggagagg gggcaggagc aggaggaggg	540
gcaggagggg caggagcagg aggaggggca ggaggggcagg gaggggcagg agcaggagga	600
ggggcaggag caggaggggc aggaggggca ggaggggcagg gaggcaggagg ggcaggagca	660
ggaggagggg caggaggggc aggaggggca ggagcaggag gggcaggagc aggaggggca	720
ggagcaggag gggcaggagc aggaggggca ggaggggcagg gaggcaggagg ggcaggaggg	780
gcaggagcag gaggggcagg aggggcagga gcaggagagg gggcaggagg ggcaggagca	840
ggaggagggg caggaggggc aggagcagga ggggcaggag gggcaggagc aggaggggca	900
ggaggggcag gaggcaggagg ggcaggaggg gcaggagcag gaggaggggc aggagcagga	960
ggggcaggag caggagggtg aggccggggt cgaggaggca gtggaggccg gggtcgagga	1020
ggtagtggag gccgggggtcg aggaggtagt ggaggccgcc ggggtagagg acgtgaaaga	1080
gccagggggg gaagtcgtga aagagccagg gggagaggtc gtggacgtgg agaaaagagg	1140
cccaggagtc ccagtagtca gtcacatca tccgggtctc caccgcgcag gccccctcca	1200
ggtagaaggc catttttcca cctgtaggg gaagccgatt attttgaata ccaccaagaa	1260
ggtggcccag atggtgagcc tgacgtgcc cggggagcga tagagcaggg cccgcagat	1320
gacccaggag aaggcccaag cactggaccc cggggtcagg gtgatggagg caggcgcaaa	1380
aaaggagggt ggtttgaaa gcatcgtggt caaggagggt ccaacccgaa atttgagaac	1440
attgcagaag gttaagagc tctcctggct aggagtcacg tagaaaggac taccgacgaa	1500
ggaacttggg tcgccggtgt gttcgtatat ggaggtagta agacctccct ttacaaccta	1560
aggcgaggaa ctgcccttgc tattccacaa tgcgtcttta caccattgag tcgtctcccc	1620
tttggaatgg cccctggacc cggcccaaaa cctggcccg ctaaggagtc cattgtctgt	1680

tatttcatgg tctttttaca aactcatata tttgctgagg ttttgaagga tgcgattaag	1740
gaccttggtta tgacaaagcc cgctcctacc tgcaatatca gggtgactgt gtgcagcttt	1800
gacgatggag tagatttgcc tccctgggtt ccacctatgg tggaaagggc tgcgcgggag	1860
ggatgatgacg gagatgacgg agatgaagga ggtgatggag atgaggggtga ggaagggcag	1920
gagtga	1926

<210> 6

<211> 1254

<212> DNA

<213> Epstein Barr Virus

<220>

<221> misc_feature

<223> EBNA1t Truncated cDNA

<400> 6

atgtctgacg agggggccagg tacaggacct ggaaatggcc taggagagaa gggagacaca	60
tctggaccag aaggctccgg cggcagtgga cctcaaagaa gaggggggtga taaccatgga	120
cgaggacggg gaagaggacg aggacgagga ggcggaagac caggagcccc gggcgggtca	180
ggatcagggc caagacatag agatggtgtc cggagacccc aaaaacgtcc aagttgcatt	240
ggctgcaaag ggaccacacg tggaacagga gcaggagcag gagcgggagg ggcaggagca	300
ggaggtggag gccgggggtcg aggaggcagt ggaggccggg gtcgaggagg tagtggaggc	360
cgggggtcgag gaggtagtgg aggccgccgg ggtagaggac gtgaaagagc caggggggga	420
agtcgtgaaa gagccagggg gagaggtcgt ggacgtggag aaaagaggcc caggagtccc	480
agtagtcagt catcatcatc cgggtctcca ccgcgcaggc cccctccagg tagaaggcca	540
tttttccacc ctgtagggga agccgattat tttgaatacc accaagaagg tggcccagat	600
ggtgagcctg acgtgcccc gggagcgata gagcagggcc ccgcagatga cccaggagaa	660
ggcccaagca ctggaccccg gggtcagggg gatggaggca ggcgcacaaa aggaggggtg	720
tttgaaagc atcgtggtca aggaggttcc aaccgaaat ttgagaacat tgcagaaggt	780
ttaagagctc tcctggctag gagtacgta gaaaggacta ccgacgaagg aacttgggtc	840
gccggtgtgt tcgtatatgg aggtagtaag acctcccttt acaacctaa ggcagggaact	900
gcccttgcta ttccacaatg togtcttaca ccattgagtc gtctccctt tggaatggcc	960
cctggaccog gccacacacc tggcccgtca agggagtcca ttgtctgtta ttcatggtc	1020
tttttacaaa ctcatatatt tgctgagggt ttgaaggatg cgattaagga ccttggtatg	1080
acaaagcccc ctctacactg caatatcagg gtgactgtgt gcagctttga cgatggagta	1140
gatttgctc cctggtttcc acctatggtg gaaggggctg ccgcggaggg tgatgacgga	1200
gatgacggag atgaaggagg tgatggagat gagggtagg aagggcagga gtga	1254

<210> 7

<211> 921

<212> DNA

<213> Epstein Barr Virus

<220>

<221> misc_feature

<223> EBNA1c Truncated cDNA

<400> 7

```

atgcgggggtc gaggaggttag tggaggccgg ggtcagaggag gtagtggagg ccgccgggggt      60
agaggacgtg aaagagccag ggggggaagt cgtgaaagag ccagggggag aggtcgtgga      120
cgtggagaaa agaggcccag gagtcccagt agtcagtcac catcatccgg gtctccaccg      180
cgcaggcccc ctccaggttag aaggccattt ttccaccctg taggggaagc cgattatttt      240
gaataccacc aagaagggtg cccagatggt gaggctgacg tgcccccggg agcgatagag      300
caggggcccc cagatgaccc aggagaaggc ccaagcactg gacccccggg tcagggtgat      360
ggaggcaggc gcaaaaaagg aggggtggtt ggaaagcatc gtggtcaagg aggttccaac      420
ccgaaatttg agaacattgc agaaggttta agagctctcc tggctaggag tcacgtagaa      480
aggactaccg acgaaggaac ttgggtcgcc ggtgtgttcg tatatggagg tagtaagacc      540
tccctttaca acctaaggcg aggaactgcc cttgctattc cacaatgtcg tcttacacca      600
ttgagtcgtc tcccctttgg aatggccctt ggaccgggcc cacaacctgg ccgcgtaagg      660
gagtccattg tctgttattt catggtcttt ttacaaactc atatatttgc tgaggttttg      720
aaggatgcga ttaaggacct tgttatgaca aagcccgtc ctacctgcaa tatcagggtg      780
actgtgtgca gctttgacga tggagtagat ttgcctccct ggtttccacc tatggtggaa      840
ggggctgccg cggagggtga tgacggagat gacggagatg aaggaggtga tggagatgag      900
ggtgaggaag ggcaggagtg a                                     921

```

<210> 8

<211> 1014

<212> DNA

<213> Epstein Barr Virus

<220>

<221> misc_feature

<223> EBNA1s Truncated cDNA

<400> 8

```

atgcggagag gcggcgacaa ccacggcagg ggcagaggcc ggggaagagg cagaggcggc      60
ggaaggcctg gcgcccctgg cggcagcggc tccggcccca gacaccgga cggcgtgcgg      120
agaccccaga agcggcccag ctgcatcgcc tgcaagggca cccacggcgg cacaggcgct      180
ggcgcagggg ctggcggagc cggagccggg ggagggggcg agaagaggcc cagaagcccc      240
agcagccaga gcagcagcag cggcagcccc ccagaaaggc cccctcccgg caggcggccc      300
ttcttcacac ccgtgggcga ggccgactac ttcgagtacc accaggaagg cggccctgac      360
ggcagccccg acgtgcctcc tggcgccatc gagcagggcc ccgcagatga cccaggagaa      420
ggccaagca ctggaccccg gggtcagggt gatggaggca ggcgcaaaaa aggagggtgg      480

```

```

tttgaaagc atcgtggtca aggaggttcc aacccgaaat ttgagaacat tgcagaaggt      540
ttaagagctc tcctggctag gagtcacgta gaaaggacta ccgacgaagg aacttgggtc      600
gccggtgtgt tcgtatatgg aggtagtaag acctcccttt acaacctaa gcgaggaact      660

gcccttgcta ttccacaatg tcgtcttaca ccattgagtc gtctccctt tggaatggcc      720
cctggaccgg gccacaaacc tggcccgcta agggagtcca ttgtctgtta tttcatggtc      780
tttttacaaa ctcatatatt tgctgaggtt ttgaaggatg cgattaagga ccttgttatg      840
acaaagcccc ctctactctg caatatcagg gtgactgtgt gcagctttga cgatggagta      900
gatttgccct cctggtttcc acctatggtg gaaggggctg ccgcgagggg tgatgacgga      960
gatgacggag atgaaggagg tgatggagat gagggtgagg aagggcagga gtga      1014

```

<210> 9

<211> 1750

<212> DNA

<213> Epstein Barr Virus

<220>

<221> misc_feature

<223> Complete oriP

<400> 9

```

gtagctaccg ataagcggac cctcaagagg gcattagcaa tagtgtttat aaggcccccct      60
tgttaaccct aaacgggtag catatgcttc ccgggtagta gtatatacta tccagactaa      120
ccctaattca atagcatatg ttacccaacg ggaagcatat gctatcgaat tagggttagt      180
aaaagggtcc taaggaacag cgatatctcc caccocatga gctgtcacgg ttttatttac      240
atggggctcag gattccacga gggtagtgaa ccattttagt cacaagggca gtggctgaag      300
atcaaggagc gggcagtgaa ctctcctgaa tcttcgctg cttcttcatt ctcttcgtt      360
tagctaatag aataactgct gagtttgtaa cagtaagggt tatgtgaggt gctcgaaaac      420
aaggtttcag gtgacgcccc cagaataaaa tttggacggg ggggttcagt gtggcattgt      480
gctatgacac caatataacc ctcacaaacc ccttgggcaa taaatactag tgtaggaatg      540
aaacattctg aatatcttta acaatagaaa tccatggggg ggggacaagc cgtaaagact      600
ggatgtccat ctcacacgaa tttatggcta tgggcaacac ataatcctag tgcaatatga      660
tactgggggtt attaagatgt gtcccaggca gggaccaaga cagggtgaacc atgttggtac      720
actctatttg taacaagggg aaagagagtg gacgccgaca gcagcggact ccactgggtg      780
tctctaacac ccccgaaaat taaacggggc tccacgcaa tggggcccat aaacaaagac      840
aagtggccac tctttttttt gaaattgtgg agtgggggca cgcgtcagcc cccacacgcc      900
gccctgcggt tttggactgt aaaataaggg tgtaataact tggctgattg taaccccgct      960
aaccactgcg gtcaaacccac ttgccacaa aaccactaat ggcaccccg ggaatacctg      1020
cataagtagg tgggcggggc aagatagggg cgcgattgct gcgatctgga ggacaaatta      1080
cacacacttg cgcctgagcg ccaagcacag ggttggttgt cctcatattc acgaggtcgc      1140
tgagagcagg ctgggtatct attggatgag ctaggatata ctacggcaat atctggatag      1200

```

```

cgagagcacy gggggcctaat gctggcctgg gtagcatata ctacccaaat atctggatag      1200
catatgctat cctaactctat atctgggtag cataggctat cctaactctat atctgggtag      1260
catatgctat cctaactctat atctgggtag tatatgctat cctaatttat atctgggtag      1320
cataggctat cctaactctat atctgggtag catatgctat cctaactctat atctgggtag      1380
tatatgctat cctaactctgt atccgggtag catatgctat cctaatagag attagggtag      1440
tatatgctat cctaatttat atctgggtag catatactac ccaaatatct ggatagcata      1500
tgctatccta atctatatct gggtagcata tgctatccta atctatatct gggtagcata      1560
ggctatccta atctatatct gggtagcata tgctatccta atctatatct gggtagtata      1620
tgctatccta atttatatct gggtagcata ggctatccta atctatatct gggtagcata      1680
tgctatccta atctatatct gggtagtata tgctatccta atctgtatcc gggtagcata      1740
tgctatcctc                                     1750

```

<210> 10

<211> 866

<212> DNA

<213> Epstein Barr Virus

<220>

<221> misc_feature

<223> Truncated oriP

<400> 10

```

accctaaacg ggttagcatat gcttcccggg tagtagtata tactatccag actaaccta      60
attcaatagc atatgttacc caacgggaag catatgctat cgaattaggg ttagtaaaag      120
ggtcctaagg aacagcgatg taggtgggcg ggccaagata gggggcgcgat tgctgcgac      180
tggaggacaa attacacaca cttgcgcctg agcgccaagc acagggttgt tggtcctcat      240
attcacgagg tgcgtgagag cacggtgggc taatgttgcc atgggtagca tatactaccc      300
aaatatctgg atagcatatg ctatcctaat ctatatctgg gtagcatagg ctatcctaat      360
ctatatctgg gtagcatatg ctatcctaat ctatatctgg gtagtatatg ctatcctaat      420
ttatatctgg gtagcatagg ctatcctaat ctatatctgg gtagcatatg ctatcctaat      480
ctatatctgg gtagtatatg ctatcctaat ctgtatccgg gtagcatatg ctatcctaat      540
agagattagg gtagtatatg ctatcctaat ttatatctgg gtagcatata ctacccaaat      600
atctggatag catatgctat cctaactctat atctgggtag catatgctat cctaactctat      660
atctgggtag cataggctat cctaactctat atctgggtag catatgctat cctaactctat      720
atctgggtag tatatgctat cctaatttat atctgggtag cataggctat cctaactctat      780
atctgggtag catatgctat cctaactctat atctgggtag tatatgctat cctaactctgt      840
atccgggtag catatgctat cctcat                                     866

```

<210> 11

<211> 308

<212> PRT

<213> Artificial

<220>

<223> Protein coded by EBNA1c-CO

<400> 11

```

Met Arg Gly Arg Gly Gly Ser Gly Gly Arg Gly Arg Gly Gly Ser Gly
1          5          10          15

Gly Arg Arg Gly Arg Gly Arg Glu Arg Ala Arg Gly Gly Ser Arg Glu
          20          25          30

Arg Ala Arg Gly Arg Gly Arg Gly Arg Gly Glu Lys Arg Pro Arg Ser
          35          40          45

Pro Ser Ser Gly Ala Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg
          50          55          60

Pro Pro Pro Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp
65          70          75          80

Tyr Phe Glu Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val
          85          90          95

Pro Pro Gly Ala Ile Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu Gly
          100          105          110

Pro Ser Thr Gly Pro Arg Gly Gln Gly Asp Gly Ala Arg Arg Lys Lys
          115          120          125

Gly Gly Trp Phe Gly Lys His Arg Gly Gln Gly Gly Ser Asn Pro Lys
          130          135          140

Phe Glu Asn Ile Ala Glu Gly Leu Arg Ala Leu Leu Ala Arg Ser His
145          150          155          160

Val Glu Arg Thr Thr Asp Glu Gly Thr Trp Val Ala Gly Val Phe Val
          165          170          175

Tyr Gly Gly Ser Lys Thr Ser Leu Tyr Asn Leu Arg Arg Gly Thr Ala
          180          185          190

Leu Ala Ile Pro Gln Cys Arg Leu Thr Pro Leu Ser Arg Leu Pro Phe
          195          200          205

Gly Met Ala Pro Gly Pro Gly Pro Gln Pro Gly Pro Leu Arg Glu Ser
          210          215          220

Ile Val Cys Tyr Phe Met Val Phe Leu Gln Thr His Ile Phe Ala Glu
225          230          235          240

Val Leu Lys Asp Ala Ile Lys Asp Leu Val Met Thr Lys Pro Ala Pro
          245          250          255

```

Thr Cys Asn Ile Arg Val Thr Val Cys Ser Phe Asp Asp Gly Val Asp
260 265 270

Leu Pro Pro Trp Phe Pro Pro Met Val Glu Gly Ala Ala Ala Glu Gly
275 280 285

Asp Asp Gly Asp Asp Gly Asp Glu Gly Gly Asp Gly Asp Glu Gly Glu
290 295 300

Glu Gly Gln Glu
305

<210> 12

<211> 337

<212> PRT

<213> Artificial

<220>

<223> Protein coded by EBNA1s-CO

<400> 12

Met Arg Arg Gly Gly Asp Asn His Gly Arg Gly Arg Gly Arg Gly Arg
1 5 10 15

Gly Arg Gly Gly Gly Arg Pro Gly Ala Pro Gly Gly Ser Gly Ser Gly
20 25 30

Pro Arg His Arg Asp Gly Val Arg Arg Pro Gln Lys Arg Pro Ser Cys
35 40 45

Ile Gly Cys Lys Gly Thr His Gly Gly Thr Gly Ala Gly Ala Gly Ala
50 55 60

Gly Gly Ala Gly Ala Gly Gly Gly Gly Glu Lys Arg Pro Arg Ser Pro
65 70 75 80

Ser Ser Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg Pro Pro Pro
85 90 95

Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp Tyr Phe Glu
100 105 110

Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val Pro Pro Gly
115 120 125

Ala Ile Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu Gly Pro Ser Thr
130 135 140

Gly Pro Arg Gly Gln Gly Asp Gly Ala Arg Arg Lys Lys Gly Gly Trp
145 150 155 160

Phe Gly Lys His Arg Gly Gln Gly Gly Ser Asn Pro Lys Phe Glu Asn
165 170 175

Ile Ala Glu Gly Leu Arg Ala Leu Leu Ala Arg Ser His Val Glu Arg
180 185 190

Thr Thr Asp Glu Gly Thr Trp Val Ala Gly Val Phe Val Tyr Gly Gly
195 200 205

Ser Lys Thr Ser Leu Tyr Asn Leu Arg Arg Gly Thr Ala Leu Ala Ile
210 215 220

Pro Gln Cys Arg Leu Thr Pro Leu Ser Arg Leu Pro Phe Gly Met Ala
225 230 235 240

Pro Gly Pro Gly Pro Gln Pro Gly Pro Leu Arg Glu Ser Ile Val Cys
245 250 255

Tyr Phe Met Val Phe Leu Gln Thr His Ile Phe Ala Glu Val Leu Lys
260 265 270

Asp Ala Ile Lys Asp Leu Val Met Thr Lys Pro Ala Pro Thr Cys Asn
275 280 285

Ile Arg Val Thr Val Cys Ser Phe Asp Asp Gly Val Asp Leu Pro Pro
290 295 300

Trp Phe Pro Pro Met Val Glu Gly Ala Ala Ala Glu Gly Asp Asp Gly
305 310 315 320

Asp Asp Gly Asp Glu Gly Gly Asp Gly Asp Glu Gly Glu Glu Gly Gln
325 330 335

Glu

<210> 13

<211> 927

<212> DNA

<213> Artificial

<220>

<223> EBNA1c-CO cDNA

<400> 13

atgcggggca gaggcggcag cggcggcaga ggaagaggcg gctctggcgg cagacgggga	60
agaggacgcg aaagagctag gggagggagc cgggagagag ccagaggcag aggccgggga	120
cggggcgaga agcggcccag aagccccagc tctggcggcc agtcctcttc tagtgggtcc	180
ccccccagaa ggccccctcc cggcaggcgg cccttcttcc accccgtggg cgaggccgac	240
tacttogagt accatcagga aggcggacca gaaggcgagc ccgacgtgcc tctgggggcc	300
atcgaacagg gccccgccga cgatcctggc gagggaccca gcaccggccc tcgaggacag	360
ggagacggcg ccaggcggaa gaagggcggc tggttcggca agcacagagg ccagggaggg	420
tccaacccca agttcgagaa tatcgccgag ggctgagag ccctgctggc ccggtccac	480
gtggagcgga ccaccgacga gggcacctgg gtggccggcg tgttcgtgta cggcggcagc	540

```

aagaccagcc tgtacaacct ggggagaggg accgccctgg ccatacccca gtgccggctg      600
acaccactct cccgcctccc ttttgcatg gctccagggc ctggacctca gcctggcccc      660
ctgcgggaga gcatcgtgtg ctacttcatt gtgtttctgc agaccacat cttcgccgag      720
gtgctgaagg acgccatcaa ggacctggtg atgaccaagc ctgccccac ctgcaacatc      780
cgggtgaccg tgtgcagctt cgacgacggc gtggacctgc cccctctggt ccccccatg      840
gtggaaggag ccgctgcaga gggcgacgat ggcgatgatg gtgacgaagg tggggacggc      900
gacgaaggcg aggaaggcca ggaatga                                     927

```

<210> 14

<211> 1014

<212> DNA

<213> Artificial

<220>

<223> EBNA1s-CO cDNA

<400> 14

```

atgcggagag gcggcgacaa ccacggcagg ggcagaggcc ggggaagagg cagaggcggc      60
ggaaggcctg gcgcccctgg cggcagcggc tccggcccca gacaccggga cggcgtgcgg      120
agaccccaga agcggcccag ctgcacggcg tgcaagggca cccacggcgg cacaggcgct      180
ggcgcagggg ctggcggagc cggagccggg ggagggggcg agaagaggcc cagaagcccc      240
agcagccaga gcagcagcag cggcagcccc ccagaaaggc cccctcccgg caggcggccc      300
ttcttcacac ccgtgggcca ggccgactac ttcgagtacc accaggaagg cggccctgac      360
ggcgagcccc acgtgcctcc tggcgccatc gacgagggcc ccgcgacga tccctggcag      420
ggacccagca ccggccctcg aggacaggga gacggcgcca ggcggaagaa gggcggctgg      480
ttcggcaagc acagaggcca gggagggtcc aaccccaagt tcgagaatat cgcgaggggc      540
ctgagagccc tgctggcccc gtcccacgtg gagcggacca ccgacgaggg cacctgggtg      600
gccggcgtgt tcgtgtacgg cggcagcaag accagcctgt acaacctgcg gagaggcacc      660
gccttgggca tccccagtg ccggctgaca ccaactctcc gcctcccttt tggcatggt      720
ccagggcctg gacctcagcc tggccccctg cgggagagca tcgtgtgcta cttcatggtg      780
tttctgcaga cccacatctt cgcgaggtg ctgaaggacg ccataagga cctggtgatg      840
accaagcctg cccccacctg caacatccgg gtgacctgtg gcagcttcga cgacggcgtg      900
gacctgcccc cctggttccc ccccatggtg gaaggagccg ctgcagaggg cgacgatggc      960
gatgatggtg acgaagggtg ggacggcgac gaaggcgagg aaggccagga atga          1014

```

<210> 15

<211> 78

<212> PRT

<213> Herpes Simplex Virus

<400> 15

Ala Pro Pro Thr Asn Val Ser Leu Gly Asn Gly Leu His Leu Asn Gly

```

Ala Glu Glu Thr Asp Val Ser Leu Gly Asp Glu Leu His Leu Asp Gly
1           5           10           15

Glu Asp Val Ala Met Ala His Ala Asp Ala Leu Asp Asp Phe Asp Leu
20           25           30

Asp Met Leu Gly Asp Gly Asp Ser Pro Gly Pro Gly Phe Thr Pro His
35           40           45

Asp Ser Ala Pro Tyr Gly Ala Leu Asp Met Ala Asp Phe Glu Phe Glu
50           55           60

Gln Met Phe Thr Asp Ala Leu Gly Ile Asp Glu Tyr Gly Gly
65           70           75

```

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US61071760B](#) [0001] [0055]
- [WO2007048601A](#) [0005] [0054]
- [WO2002090533A](#) [0006] [0054]
- [WO2006096989A](#) [0007] [0054]
- [WO2005024030A](#) [0054]

Non-patent literature cited in the description

- **MIZUGUCHI HHOSONO THAYAKAWA T.** Long-term replication of Epstein-Barr virus-derived episomal vectors in the rodent cells *FEBS Lett*, 2000, vol. 472, 2-3173-8 [0054]
- **DUROCHER, YPERRET, STHIBAudeau, EGAUMOND, MHKAMEN, ASTOCCO. RABRAMOVITZ, M.** A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture *Analytical Biochemistry*, 2000, vol. 284, 2316-26 [0054]

- **BOUSSIF OZANTA MABEHR J**Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-foldGene Ther, 1996, vol. 3, 121074-80 [0054]
- **THOMAS MLU JJGE QZHANG CCHEN JKLIBANOV AM**Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lungProc Natl Acad Sci U S A, 2005, vol. 102, 165679-84 [0054]
- **KANG MSHUNG SCKIEFF EE**Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growthProc Natl Acad Sci U S A, 2001, vol. 98, 2615233-8 [0054]
- **SEARS JKOLMAN JWAHL GMAIYAR AM**Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1J Virol, 2003, vol. 77, 2111767-80 [0054]
- **KENNEDY G.SUGDEN B.**EBNA1, a bifunctional transcriptional activatorMol Cell Biol, 2003, vol. 23, 196901-8 [0054]
- **PHIEL CJZHANG FHUANG EYGUENTHER MGLAZAR MAKLEIN PSH**Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogenJ Biol Chem, 2001, vol. 276, 3936734-41 [0054]
- **CHEN JGHAZAWI FIMBAKKAR WLI Q**Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase BMol Cancer, 2006, vol. 5, 71- [0054]
- **SHENG ZLIANG YLIN CYCOMAI LCHIRICO WJ**Direct regulation of rRNA transcription by fibroblast growth factor 2Mol Cell Biol, 2005, vol. 25, 219419-26 [0054]
- **KISHIDA TASADA HKUBO KSATO YTSHIN-YA MIMANISHI JYOSHIKAWA KMAZDA O.**Pleiotrophic functions of Epstein-Barr virus nuclear antigen-1 (EBNA1) and oriP differentially contribute to the efficacy of transfection/expression of exogenous gene in mammalian cellsJournal of Biotechnology, 2007, [0054]
- **ETTEHADIEH EWONG-MADDEN SALDRICH TLANE KMORRIS AE**Over-expression of protein kinase B α enhances recombinant protein expression in transient systemsCytotechnology, 2002, vol. 38, 11-14 [0054]
- **KRYSAN PJCALOS MPE**Epstein-Barr virus-based vectors that replicate in rodent cellsGene, 1993, 137-143 [0054]
- **TOMIYASU KSATOH EODA YNISHIZAKI KKONDO MIMANISHI JMAZDA O**Gene transfer in vivo and in vitro wit hEpstein-Barr virus-based episomal vector results in markedly high transient expression in rodent cellsBiochem Biophys Res Comm, 1998, vol. 253, 733-738 [0054]

PATENTKRAV

1. Ekspressionssystem til stabil ekspression af et gen af interesse, hvilket ekspressionssystem omfatter: en første vektor med en Epstein-Barr-virus nuklear antigen-1- (EBNA1) nukleotidsekvens, der koder for et protein, der består af EBNA1c, EBNA1t eller
5 EBNA1s som vist i Figur 1, en promoter og et polyadenyleringssignal for EBNA1-nukleotidsekvensen og en oriP-nukleotidsekvens; og en anden vektor med et gen af interesse, en promoter og et polyadenyleringssignal for genet af interesse og en oriP-nukleotidsekvens.
- 10 2. Ekspressionssystem ifølge krav 1, hvor EBNA1-proteinet består af SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 11 eller SEQ ID NO: 12.
3. Ekspressionssystem ifølge krav 1 eller 2, hvor EBNA1-nukleotidsekvensen er kodon-optimeret.
- 15 4. Ekspressionssystem ifølge krav 1, hvor Epstein-Barr-virus nuklear antigen-1- (EBNA1) nukleotidsekvensen består af SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 13 eller SEQ ID NO: 14.
- 20 5. Ekspressionssystem ifølge et hvilket som helst af de foregående krav, hvor oriP-nukleotidsekvenserne i den første og den anden vektor uafhængigt omfatter SEQ ID NO: 9 eller SEQ ID NO: 10.
- 25 6. Fremgangsmåde in vitro til stabil ekspression af et gen af interesse i pattedyreceller, hvilken fremgangsmåde omfatter: transfektion af en pattedyrecelle med et ekspressionssystem som defineret i et hvilket som helst af de foregående krav; og replikation af cellen for at tilvejebringe pattedyreceller, der stabilt udtrykker genet af interesse.
- 30 7. Fremgangsmåde ifølge krav 6, hvor transfektion af cellen med den første og den anden vektor udføres samtidigt, eller cellen transficeres med én af vektorerne først for at frembringe en stabil klon efterfulgt af transfektion med den anden vektor for at frembringe en klon, der stabilt udtrykker genet af interesse.
8. Fremgangsmåde ifølge krav 6 eller 7, hvor pattedyrecellerne er udvalgt fra gruppen

bestående af kinesiske hamsterovarie- (CHO) celler, humane embryonyreceller 293 (HEK293) og Madin-Darby-hundenyre- (MDCK) celler.

9. Fremgangsmåde ifølge et hvilket som helst af kravene 6 til 8, hvor pattedyrecellerne er
- 5 kinesiske hamsterovarie- (CHO) celler.

DRAWINGS




Fig. 1




Fig. 2




Fig. 3A





Fig. 3B

A



B




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8





Fig. 9




Fig. 10




Fig. 11




Fig. 12